Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Stock Watch: J&J And Roche Invite Comparison

Early Q1 Earnings Reports Highlight Challenges And Green Shoots

Executive Summary

Recovering pharmaceutical and medical device revenues at J&J hint at the green shoots germinating from the pandemic. Roche’s COVID-19 diagnostics revenue growth was its own green shoot, but can these be maintained as the pandemic evolves?

You may also be interested in...



Stock Watch: Novartis And Lilly Pour Cold Water On Q1 Earnings

Novartis’s comparatively anemic revenue growth and Lilly’s sales shortfall suggest that hopes for an immediate sector recovery from the pandemic are premature.

J&J Device Businesses Return To Growth Led By Electrophysiology And Surgery

The health care giant’s medical device revenues grew 8.8% in the first quarter, reflecting the recovery of interventions and surgeries since the start of the pandemic.

Roche: Most Of Avastin Business In Europe Is Now Gone

Several biosimilars to Roche’s Avastin are now available in Europe following market formation in June last year, adding to Roche’s woes for its legacy oncology drugs, including MabThera/Rituxan and Herceptin.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC144246

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel